Supplemental
aIRR, adjusted incidence rate ratio; p het , p-value for heterogeneity (obtained using a likelihood ratio test and provided for variables with more than two levels), p trend , p-value for trend (obtained by fitting a model in which the specified variable has one degree of freedom); AVGLO, average daily global solar radiation; MTOR, mammalian target of rapamycin; NE, not estimable due to no cases among the exposed group (but not statistically significant) *Includes T-cell depleting polyclonal antibody, T-cell depleting monoclonal antibody, interleukin-2 receptor antagonist, and alemtuzumab **Analyzed only among kidney recipients ***Analyzed only among kidney recipients beginning at 1.5 years post-transplant, based on rejection episodes documented by transplant programs on follow-up reports for the first year post-transplant.
